CDK20 and hepatocellular carcinoma: This includes, for instance, the identification of cyclin-dependent kinase 20 (CDK20) as a novel target in hepatocellular carcinoma and generation of potent CDK20 inhibitors using the generative chemistry platform Chemistry42 coupled with subsequent in vitro explorations [30, 45].